In The News

Biogen’s Rehearing Denial Lays New Hurdles for Pharma Patents

Bloomberg Law

18 Mar 2022

Matthew Chivvis spoke to Bloomberg Law about a recent dissent from three Federal Circuit judges, signaling that a potential Supreme Court petition might be on the horizon in Biogen International GmbH v. Mylan Pharmaceuticals Inc., which opened up a new avenue for challenging pharmaceutical patents.

“It’s an area where I have alerts set up for every written description precedential opinion coming out because they’re so impactful for my clients,” Matthew said. “It doesn’t matter what side they think they’re going to be on. They want to know what’s going on here just because it’s become the center of a bunch of big decisions recently.”

Read the full article (subscription required).



Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.